| Cell line name |
MR49C |
|---|
| Synonyms |
ENZR 49C; 49CENZR |
|---|
| Accession |
CVCL_RW52 |
|---|
| Resource Identification Initiative |
To cite this cell line use: MR49C (RRID:CVCL_RW52) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_68534; Enzalutamide (Xtandi; MDV-3100).
Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
- Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
|
|---|
| Disease |
Prostate carcinoma (NCIt: C4863) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0395 (LNCaP) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
50Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=25634993; DOI=10.1158/1078-0432.CCR-14-1108
Yamamoto Y., Loriot Y., Beraldi E., Zhang F., Wyatt A.W., Al Nakouzi N., Mo F., Zhou T.-Y., Kim Y., Monia B.P., MacLeod A.R., Fazli L., Wang Y.-Z., Collins C.C., Zoubeidi A., Gleave M.E.
Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Clin. Cancer Res. 21:1675-1687(2015) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_RW52
|
|---|
| Encyclopedic resources |
Wikidata; Q54906575
|
|---|
| Entry history |
|---|
| Entry creation | 05-Mar-2018 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 11 |
|---|
